Navigation Links
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Susquehanna Healthcare Conference
Date:3/3/2008

ROCKVILLE, Md., March 3 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that a panel presentation and discussion at the Susquehanna Financial Group Second Annual SIGnificant Investment Options in Healthcare Conference will be webcast and may be accessed at http://www.hgsi.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO )

A senior member of Human Genome Sciences' clinical management team will participate in a panel presentation and discussion entitled "Potential New Therapies in SLE" on Wednesday, March 5, 2008.

Investors interested in listening to a replay of this panel discussion should log on after 6:00 pm on March 5, 2008 to access the audio recording.

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

HGS and Human Genome Sciences are registered trademarks of Human Genome Sciences, Inc. For additional information on Human Genome Sciences, Inc., visit the company's web site at http://www.hgsi.com.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets
2. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
3. Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress
4. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
5. Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors
6. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2007 Financial Results
7. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
8. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
9. Human Genome Sciences and Xencor Announce Antibody Collaboration
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Stemagen First to Create Cloned Human Embryos From Adult Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016 The report "Acrylic Processing Aid Market by Polymer Type (PVC), ... Goods) - Global Forecast to 2026", published by MarketsandMarkets, the global market size ... Million by 2026, registering an of CAGR of 6.2% between 2016 and 2026. ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... 2016  Genprex, Inc. a biopharmaceutical company focused ... today announced that it has retained ICR Healthcare, ... communications and advisory firm, to develop and implement ... combine investor relations, public relations and digital communications ... of Genprex and its lead candidate Oncoprex, which ...
(Date:12/7/2016)... ANN ARBOR, Mich. , Dec. 7, ... developing breakthrough immune modulatory medicines, announced today the initiation ... lead therapeutic candidate, LYC-30937- E nteric C oated, ... skin disease that is estimated to affect as many ... , with approximately 1.5 - 3 million cases ...
(Date:12/7/2016)... ... December 07, 2016 , ... Cambrian ... for industrial facilities, today announced that one of the nation’s fastest growing craft ... novel water-energy purchase agreement (WEPA). Under the WEPA, a first for the industrial ...
Breaking Biology Technology:
(Date:12/6/2016)... Ind. , Dec. 6, 2016  Zimmer Biomet Holdings, ... it has priced an offering of €500.0 million principal amount ... million principal amount of its 2.425% senior unsecured notes due ... expected to occur on December 13, 2016, subject to the satisfaction ... an annual basis. The ...
(Date:12/2/2016)... India , December 1, 2016 ... Authentication type (Fingerprint, Voice), Future Technology (Iris Recognition ... and Region - Global Forecast to 2021", published ... USD 442.7 Million in 2016, and is projected ... at a CAGR of 14.06%.      ...
(Date:11/29/2016)... 29, 2016 BioDirection, a privately held medical ... the objective detection of concussion and other traumatic brain ... completed a meeting with the U.S. Food and Drug ... Pre-Submission Package. During the meeting company representatives reviewed plans ... precursor to commencement of a planned pilot trial. ...
Breaking Biology News(10 mins):